A rise in the number of aged people worldwide is helping the global epigenetics drugs and diagnostic technologies market grow rapidly. This, in turn, is attributable to the strong correlation between aging and various types of diseases. Between 2000 and 2050, the global geriatric population (60 years and above) is expected to double, the WHO reckons.
The organization expects that 22% of the global population would comprise people aged 60 years or more. This age group carries a higher risk of diseases such as cancer. Owing to the increasing economic burden of diseases such as cancer and diabetes, governments across the world are advocating the adoption of early disease detection and diagnosis. Early cancer detection, especially, is being encouraged through screening kids such as Epi ProLung and Epi Procolon.
This is aiding the growth of the global epigenetics drugs and diagnostic technologies market, states the report. Epigenetic drugs are considered effective because they can help reverse aberrant gene expression, which could lead to various diseases. Histone Deacetylase (HDAC) and DNA methyltransferase (DNMT) are the inhibitors that regulate cellular expression. Of these, DNA methyltransferases hold a larger share in the market as they offer improved pathways to target cancerous cells. The FDA-approved drugs that are currently available commercially include DNMT inhibitors, Vidaza (azacitidine) by Celgene and Dacogen (decitabine) from Eisai.
These drugs have been approved for treating Myelodysplastic Syndrome (MDS). The epigenetics drugs market also features Zolinza (vorinostat) by Merck and Istodax (romidepsin) from Celegne, which are both HDAC inhibitors and have been approved for treating Cutaneous T Cell Lymphoma (CTCL). However, epigenetics is stretching beyond oncology and is proving effective in several non-oncology indications, including arthritis and Alzheimer’s.
This will give companies in the global epigenetics drugs and diagnostic technologies market a larger playing field. North America represents the largest regional market for epigenetics. Over the forecast period of the report, it is expected that the region will continue to remain in a dominant position, accounting for about 50% of the global market for epigenetics. The demand for epigenetic drugs and diagnostic technologies in this region stems largely from the high incidence of cancer here. In Asia, the scope for this market’s growth is expanding rapidly.
Asia accounts for about half all cancer cases diagnosed worldwide. This creates conducive conditions for the growth of the epigenetic drugs and diagnostics market in Asian countries, especially China, Japan, Australia, and South Korea, with Japan in the dominant position. Some of the most dominant companies in the global epigenetics drugs and diagnostic technologies market are: Merck, Celgene Corporation, Exact Sciences, Eisai Pharmaceuticals, and Epigenomics.
DriverPack Solution 2018 searches for drivers to your sound card, graphics and network , memory cards (USB), monitor, controllers, cameras, digital cameras and the individual components included in the motherboard. Installed on your system security software (antivirus, Internet Security) can block access to the application. In this container, add the name of the program to the exceptions list antivirus program. The drop-down list is also an extended version of the software available for download exclusively on BitTorrent. For this purpose, we recommend that you install the necessary software uTorrent , through which we retrieve the corresponding .torrent file (ISO).
Worldwide telemedicine markets are poised to achieve significant growth as the telemedicine systems provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on.
Left to their own judgments, some patients typically are apt to make terrible decisions relating to their personal health either because of ignorance, genetic inheritance, or because of lifestyle habit. Home telemonitoring programs need to use advanced technology. Effective monitors support patient education. They support timely clinician intervention based on real vital signs data gathered on a daily basis.
0 Response to "Global Epigenetics Drugs And Diagnostic Technologies Market To Account For US$5.7 Bn By 2018"
Post a Comment